Eikon Therapeutics
Clinical trials sponsored by Eikon Therapeutics, explained in plain language.
-
New combo therapy shows promise in early cancer trial
Disease control CompletedThis early-stage study tested an experimental drug called BDB001, alone or with another drug (atezolizumab), in 40 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find a safe dose and check for side effects. Researchers a…
Phase: PHASE1 • Sponsor: Eikon Therapeutics • Aim: Disease control
Last updated May 17, 2026 04:34 UTC
-
New combo therapy for advanced tumors shows early promise
Disease control CompletedThis early-stage trial tested a new drug called BDB001, alone or with another drug (pembrolizumab), in people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the best dose. Only one person took part, so res…
Phase: PHASE1 • Sponsor: Eikon Therapeutics • Aim: Disease control
Last updated May 17, 2026 04:31 UTC
-
New hope for patients whose tumors resist immunotherapy?
Disease control CompletedThis study tested an experimental drug called BDB001 in people with advanced solid tumors that had stopped responding to standard immunotherapy (PD-1 or PD-L1 blockers). The goal was to see if BDB001 could shrink tumors or slow their growth. Only one person was enrolled, so resul…
Phase: PHASE2 • Sponsor: Eikon Therapeutics • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
New combo therapy tested for tough cancers
Disease control CompletedThis early-phase study tested an experimental drug called BDB001, given alone or with pembrolizumab, in 87 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the best dose. This is not a cure; it aims…
Phase: PHASE1 • Sponsor: Eikon Therapeutics • Aim: Disease control
Last updated May 13, 2026 16:00 UTC